ND-003 (NewDEL Biotech)

Tier C — Watch / trade

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：RET, Trk, KIT, CSF1R, DDR

Indications (approved)：Idiopathic pulmonary fibrosis, Gastrointestinal stromal tumour, 肾脏纤维化, Atopic dermatitis, Chronic renal impairment, Solid tumour, Pulmonary fibrosis, Neoplasm

Regional status

Phase I

2023-07-14

China

Phase II

2026-08-18

Japan

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of ND-003 (NewDEL Biotech)?

Approved indications include: Idiopathic pulmonary fibrosis, Gastrointestinal stromal tumour, 肾脏纤维化, Atopic dermatitis, Chronic renal impairment, Solid tumour, Pulmonary fibrosis, Neoplasm.

When does the ND-003 (NewDEL Biotech) patent expire?

No public expiry year is available for ND-003 (NewDEL Biotech) yet; this page updates once verified.

How do I get a quote for ND-003 (NewDEL Biotech) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29